Icatibant Xiromed

Icatibant, the active ingredient in Icatibant Xiromed, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency.

GNH USA supplies Icatibant Xiromed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

Hereditary angioedema type I: rapid reduction of swelling during acute attacks. Hereditary angioedema type II: prompt symptom control when attacks occur. Hereditary angioedema in adults (any type): provides fast relief of edema and improves airway safety.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection point. - Redness or erythema: localized skin irritation. - Swelling at injection site: transient increase in local tissue volume. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or hives. - Anaphylaxis: severe allergic response requiring immediate medical attention. - Severe hypotension: sudden drop in blood pressure. - Airway angioedema: swelling that may compromise breathing. - Thrombocytopenia: low platelet count observed in rare cases. - Urticaria: widespread hives.

Before using Icatibant, consider the following safety measures.

Pregnancy: safety not established; use only if benefit outweighs potential risk. Breastfeeding: unknown safety; evaluate risk versus benefit. Renal impairment: no dosage adjustment required, but monitor renal function. Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced angioedema. Hypersensitivity: discontinue immediately if severe allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that affect the bradykinin system or immune response.

Major Interactions (Avoid): - ACE inhibitors: increased bradykinin may raise risk of angioedema. - Angiotensin II receptor blockers (ARBs): additive effect on bradykinin pathways. - Other bradykinin B2 antagonists: combined use may lead to excessive blockade.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of hypersensitivity; monitor patient. - Corticosteroids: could alter immune response; observe for infection risk.